Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus ENPRESSE 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus ENPRESSE 21.
ENOVID-E vs ENPRESSE-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive; suppresses gonadotropin release via estrogen-progestin negative feedback, preventing ovulation; alters cervical mucus and endometrial lining to inhibit sperm penetration and implantation.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
ENPRESSE-21 (ethinyl estradiol/norethindrone acetate) is an oral contraceptive. One tablet (0.035 mg ethinyl estradiol/0.5 mg norethindrone acetate) by mouth once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is 8-10 hours; this supports once-daily dosing and reaches steady state within 2-3 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal excretion of unchanged drug accounts for approximately 30-40% of the dose; hepatic metabolism accounts for the remainder, with metabolites eliminated in bile and feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive